Picture loading failed.

Anti-PDCD1 therapeutic antibody (Pre-made Prolgolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Prolgolimab is the original fully human anti-PD1 monoclonal antibody for the treatment of advanced melanoma, advanced NSCLC and metastatic cervical cancer. Pending approval in Russia for melanoma in 2019.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-458-1mg 1mg 3090
GMP-Bios-ab-458-10mg 10mg 21890
GMP-Bios-ab-458-100mg 100mg 148000
GMP-Bios-ab-458-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1 therapeutic antibody (Pre-made Prolgolimab biosimilar,Whole mAb)
INN Name Prolgolimab
TargetPDCD1/PD-1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesBiocad
Conditions Approvedna
Conditions ActiveMalignant melanoma;Cervical cancer;Non-small cell lung cancer
Conditions DiscontinuedSolid tumours
Development Techna